Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 clinical trial (NCT06541847). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of HLX-1502?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 clinical trial (NCT06541847). Contact the study team or your healthcare provider for specific answers.

Question 3

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 clinical trial (NCT06541847). Contact the study team or your healthcare provider for specific answers.

Question 4

What happens if I experience side effects or my condition worsens?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 clinical trial (NCT06541847). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any other treatment options I should consider alongside this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 clinical trial (NCT06541847). Contact the study team or your healthcare provider for specific answers.

Question 6

What is the timeline for the trial and how often will I need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 clinical trial (NCT06541847). Contact the study team or your healthcare provider for specific answers.

What this study is about